Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
SFA Therapeutics logo — A New Paradigm in Drug Development

SFA Therapeutics

A New Paradigm in Drug Development

Founded 2016 United States Jenkintown, United States 9 employees Convertible Note Total: $8.73M Biotechnology, Health Care +1

General Information

Company Name SFA Therapeutics
Founded Year 2016
Location United States Jenkintown, United States
Employees 9
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Convertible Note
Social

BounceWatch is an independent company data service, not affiliated with SFA Therapeutics. To contact SFA Therapeutics, visit sfatherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SFA Therapeutics compare?

A PDF of SFA Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SFA Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SFA Therapeutics

SFA Therapeutics is a clinical stage start-up biotech company founded in 2016 with a focus on developing compounds discovered in the human microbiome. Their patented and proprietary platform aims to immuno-modulate inflammatory factors derived from the human gut microbiome. The technology, licensed from and supported by research at Temple University in Philadelphia, positions SFA Therapeutics as a pioneer in native immunotherapy. The company's products are currently undergoing investigations in the areas of cancer, liver, and autoimmune disease, showcasing their potential to address critical health challenges in today's society. In November 2023, SFA Therapeutics successfully secured a significant $4.50M Venture Round investment from notable investors including Asymmetry Ventures, Ben Franklin Technology Partners of Southeastern Pennsylvania, North South Ventures, and Savantus Ventures. This influx of funding not only demonstrates confidence in the company's innovative approach but also provides valuable resources to further their research and development efforts. SFA Therapeutics's dedication to leveraging the human microbiome for drug development signifies a forward-thinking approach within the biotechnology and healthcare industries. As they continue to advance their unique platform, the company holds the potential to make a substantial impact in the treatment of various diseases, offering a promising investment opportunity for venture capitalists seeking to support groundbreaking solutions in the healthcare space.

Business keywords: biotech, drug development, microbiome, immunotherapy, clinical stage, patented technology, inflammatory disease, autoimmune disease, cancer treatment, liver disease, Temple University, biopharmaceutical, metabolites as drugs, immuno-modulation, startup

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note $4.50M 4
Asymmetry Ventures Ben Franklin Technology Partners of Southeastern Pennsylvania North South Ventures
Asymmetry Ventures, Ben Franklin Technology Partners of Southeastern Pennsylvania +2
09 Nov 2023
Seed Round $4.00M 6
Boost VC Ben Franklin Technology Partners INP Capital
Boost VC, Ben Franklin Technology Partners +4
20 Jun 2022
Seed Round $125.00K -
17 Aug 2021
Grant $100.00K -
18 Jun 2020

SFA Therapeutics Alternatives & Competitors

View All Alternatives
SFA Therapeutics vs
Biond Biologics Ltd
Biond Biologics Ltd Israel

Biond - Innovative immunotherapies and a pioneering intracellular delivery for biologics for the tre...

Series C
43 employees
Biotechnology, Health Care
SFA Therapeutics vs
MediMabBio
MediMabBio Korea South

A biotechnology company that focuses on developing new therapeutic drugs targeting Oncology and Infl...

Non Equity Assistance
15 employees
Biotechnology, Health Care
SFA Therapeutics vs
Apexigen
Apexigen United States

Creating Transformative Immunotherapies for Patients with Cancer

Post-IPO Equity
11 employees
Biopharma, Biotechnology
Also compare with: SFA Therapeutics vs DBV Technologies DBV Technologies View all alternatives

FAQ About SFA Therapeutics

A New Paradigm in Drug Development
SFA Therapeutics was founded in 2016.
SFA Therapeutics is headquartered in Jenkintown, United States.
SFA Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on biotech, drug development, microbiome and immunotherapy.
SFA Therapeutics has approximately 9 employees.
SFA Therapeutics has completed 4 funding rounds, raising a total of $8.73M. The latest funding stage is Convertible Note.
Top alternatives and competitors to SFA Therapeutics include Biond Biologics Ltd, MediMabBio, Apexigen, ImmunoGenesis, Inc., Tolerx, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SFA Therapeutics and Biond Biologics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SFA Therapeutics, https://bouncewatch.com/company/sfa-therapeutics, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes